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A single word, Epigenetics, underlies one exciting subject in today’s Science, with
different sides and with interactions with philosophy. The apparent trivial description
includes everything in between genotype and phenotype that occurs for a given unique
DNA sequence/genome. This Perspective article first presents an historical overview
and the reasons for the lack of consensus in the field, which derives from different
interpretations of the diverse operative definitions of Epigenetics. In an attempt to
reconcile the different views, we propose a novel concept, the “cytocrin system.”
Secondly, the article questions the inheritability requirement and makes emphasis
in the epigenetic mechanisms, known or to be discovered, that provide hope for
combating human diseases. Hopes in cancer are at present in deep need of deciphering
mechanisms to support ad hoc therapeutic approaches. Better perspectives are for
diseases of the central nervous system, in particular to combat neurodegeneration and/or
cognitive deficits in Alzheimer’s disease. Neurons are post-mitotic cells and, therefore,
epigenetic targets to prevent neurodegeneration should operate in non-dividing diseased
cells. Accordingly, epigenetic-based human therapy may not need to count much on
transmissible potential.
Keywords: nucleocrin, thermodynamics, state variables, inheritability, therapy, Alzheimer’s disease, cancer, tumor
therapy
ANCIENT ORIGINS
Discovery in the 1950s of the double helical structure of the DNA opened the era of everything
being explained by Genetics/Molecular Biology, i.e., essentially in terms of the sequence of the
genome. The lack of responses for the varied phenotypic (environmental, physiological, etc.,)
aspects displayed by living beings has led to the fashionable “Epigenetics era.” For many scientists,
the field is recent and epigenetic mechanisms consist of modifying the structure of histones and
of DNA methylation patterns. However, the field has ancient and appealing origins and it contains
more faces/cornerstones than usually considered. This Perspective article attempts to give a holistic
view of factors and players in Epigenetics. The relevant goal to achieve epigenetic-based therapies
probably awaits discovering essential clues and looking at them under an appropriate perspective.
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Epigenetics’ precursor word, “epigenesis,” was used to
confront a current of thought (alive for many centuries), which
assumed that different parts of the body of mammals were pre-
formed in the spermatozoon (preformation). Both Aristotle and
William Harvey who were born, respectively, 384 years before
Christ and in 1578, share recognition for inventing “epigenesis.”
The first putted a name (in Greek) to define the development
from, for instance, a chicken egg to a chick with beak, legs, wings,
etc., The second coined the English word for describing the same
concept. A recent review shows the origins and evolution from
epigenesis to epigenetics in a very attractive way (Deichmann,
2016). In the first part of the twentieth Century, the embryologist
ConradWaddington coined the term “Epigenetics” and, later on,
funded the first “epigenetics laboratory.”
The term may be used as an adjective or as a noun. Riggs
et al. (1996) as quoted in Haig (2004) defined epigenetics
(noun) as: “the study of mitotically and/or meiotically heritable
changes in gene function that cannot be explained by changes
in DNA sequence.” A second definition was provided by
Herring (1993) as quoted in Haig (2004): “the entire series
of interactions among cells and cell products which leads to
morphogenesis and differentiation.” Then, epigenetic may be
used as an adjective of any non-genetic mechanism underlying
morphogenesis and differentiation. The last sentence in the
abstract of the inspirational Felsenfeld (2014) review states:
“Recent discoveries about the role of these mechanisms in early
development may make it desirable to return to the original
definition of epigenetics.” As mentioned in Deichmann (2016),
Waddington defined Epigenetics as “the whole complex of
developmental processes that lie between genotype and phenotype.”
We think that this definition applies to both tissue-specific
phenotypes under development and for mechanisms providing
phenotypic diversity in adults, for instance, among genotype-
identical twins that are subject to different environmental, life-
styles, etc., constraints.
Surely, it is worth reading seminal papers and books on this
matter (Waddington, 1939, 1942, 1956; Haig, 2004; Felsenfeld,
2014) some of which are quite old (i.e., pioneering) and for this
reason not included in the PubMed database. In particular, one
article with a suggestive title “The (dual) origin of epigenetics”
(Haig, 2004) guides the reader on how to start confronting the
diverse epigenetic faces. Recommendable is also to take into
account the sections devoted to Epigenetics in the book on the
“four dimensions” of Evolution by Jablonka and Lamb (2002).
EPIGENETIC FACTORS
Britannica encyclopedia’s definition of epigenetics “the study
of the chemical modification of specific genes or gene-associated
proteins of an organism” beautifully summarizes today’s more
fashionable epigenetic traits, namely DNA methylation and
histone acetylation. The first one is a chemical modification
that regulates gene expression i.e., that contributes to turn
genes on or off. Analogously, post-translational modification
(acetylation but also methylation) of histones, which are proteins
that directly interact with DNA, is a chemical mechanism
with significant impact on gene regulation. These and other
similar -though less studied- mechanisms operate in the nucleus,
close to DNA. Quite unlikely for histone acetylation marks,
DNA methylation patterns may be clonally inherited, i.e., they
may pass to daughter cells, meaning that epigenetic factors in a
liver cell are transmitted to another liver cell, or the other way
around: upon mitosis of a kidney/muscle/etc. cell, some DNA
methylation traits are maintained in the two arising cells, i.e.,
they are clonally inherited. Recent epigenetic markers impacting
on gene expression regulation are exosomes and atypical RNAs:
micro RNAs (miRNAs) and long non-coding RNAs. At present, it
is not known whether these factors may be clonally inherited but,
importantly, exosomes are acting as endocrine factors. miRNAs
are described in mammalian body fluids and, by definition,
they are also endocrine factors. By the same token, can classical
endocrine factors, which do regulate gene expression in target
cells, be considered epigenetic factors?
THE POOR KNOWLEDGE ON
MECHANISMS
Today’s fashionable epigenetic traits and the so-called epigenome
are descriptors. A serious limitation to understand the real
relevance of specific epigenetic traits is the lack of relevant
information on mechanisms. For instance, why there are
so many histone deacetylase genes and why, how and
by whom DNA methyltransferases/demethylases and histone
acetyltransferases/deacetylases become activated and deactivated.
Also, the underlying mechanisms of the novel epigenetic
mediators are still very obscure (Wiklund et al., 2010; Celluzzi
and Masotti, 2016; Lange et al., 2017). We consider relevant that
miRNAs and exosomes may act under endocrine paradigms. In
fact, they are produced in a given organ/cell and reach another
one by traveling via body fluids. In the case of exosomes, the
gene regulation in the target cell(s) may be achieved by means
of its RNA but also by other mediators that are contained
in these vesicles. Accordingly, we find no reason to consider
that hormonal regulation does not have epigenetic character,
especially if we take into account that the endocrine regulation by
which hormones act via receptors to affect gene expression is one
of the best-known mechanisms of gene expression regulation.
THE CYTOCRIN SYSTEM. EPIGENETICS
WITHIN A WHOLE-BODY FRAMEWORK
Hormonal regulation in mammals is categorized as endocrine,
paracrine and/or autocrine. Regulation of cell phenotype in
unicellular organisms by extracellular factors (hormones or
nutrients) can only be autocrine, but the word is misleading since
some of the regulators are produced by the cell while others
are provided by the medium/environment. Actually, there is a
need to denote the single-cell equivalent to endocrine system.
Whereas, the suffix “crine” denotes something that is released to
act from the outside, the cell machinery integrates and conveys
all kind of extracellular signals to the cytoplasm and to the
nucleus to regulate gene expression. We consider that the suffix
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“crin,” which refers to something that goes down as the crin
of an animal, may be appropriate to describe this phenomenon
in a general way. The underlying idea is to consider “crin”
anything that goes from membranes inwards and can be applied
to everything confined within a membrane (e.g., cell, nucleus,
or mitochondria). Accordingly, the “cytocrin system” would
describe the top-down effect of the different molecules impacting
a unicellular organism or a single cell. Similarly, “nucleocrin”
would describe the effect of the factors conveying cytoplasmic
signals reaching the nucleus to be engaged in controlling gene
expression. As mitochondria also has DNA, the equivalent word
might be “mitochrin.”
As indicated above, nutrients are key regulators despite
not being produced by cells. Accordingly, mechanisms that
regulate cell life in a general way (nutrients constitute again a
convenient example) reach DNA and histones first in a cytocrin
and later in a nucleocrin fashion. Following the reasoning and
considering that each single cell in a mammal has its own
internal machineries, “nucleocrin” could be used to describe
mechanisms that end up activating/deactivating factors directly
affecting the chromosomal structure and function. Note the
difference between “nucleocrin” and “nucleocrine,” which was
a term coined by Radulescu (1995) to denote, in a cancer
research context, how extracellular regulators may promote cell
growth by interacting with nuclear proteins (tumor suppressors)
(Radulescu, 1995, 2015). Moreover, we feel necessary to establish
the mechanisms involved in transmitting extranuclear signals
to the nucleus: directly (acting on transcription factors), and/or
indirectly (acting on enzymes involved in managing epigenetic
traits). We also consider more relevant to decipher the epigenetic
mechanisms (triggers, activation/deactivation patterns, etc.,)
than empirically describe methylation patterns, or that a given
miRNA is increased in a given physiological circumstance or in a
given disease (see below).
FROM EPIGENETICS IN UNICELLULAR
ORGANISMS TO EPIGENETICS IN
MAMMALS
Anything impacting on a unicellular organism is prone to
provoke a reaction i.e., a specific phenotype. One of such factors is
the carbon source needed for survival. Depending on the growth
medium, the phenotype of a given organism with a given DNA
sequence could change. Taking a naïve approach, nutrients are
non-genetic (i.e., they may be considered epigenetic) factors.
Indeed, nutrients may modify DNA methylation patterns or
histone acetylation as they lead to expression of specific
transcription factor(s) and trigger gene regulation programs. The
effect of some nutrients on gene expression is mainly known after
the seminal identification of the lactose operon in bacteria by
Jacob and Monod (1961).
To our knowledge, the field of mammalian epigenetics
tends to forget the overall phenotype of an individual, which
results from a given genome but multiple epigenetic overlapping
factors and mechanisms acting under short (even in hours) and
long-term (homeostatic/permanent-like) paradigms and during
development but also in the adult individual. Epigenetics seems
to be restricted to the development of multicellular organisms,
i.e., to explain how a body containing billions of cells and
dozens of cell types (with the same DNA) arises from a
single cell. We propose to forget this limitation and expand
“epigenetic” to any factor that, without involvement of DNA
alterations, is affecting the phenotype of a mammal (or any
of its cell types). Daughter cells resulting from a single ovum
(having the same DNA) start to be different very soon, just
when molecules, mainly nutrients, impact cells unevenly. Surely,
one of the first mechanisms of control of gene expression
in a developing embryo arises from concentration gradients,
for instance, when oxygen reaches more concentration in
one cell than in another. Oxygen gradients are essential for
development. Why oxygen may be an epigenetic factor during
development but not in adult life? Similar to oxygen, and as
indicated above for unicellular organisms, nutrients coming from
placenta and also metabolites (ATP, adenosine, amino acids,
etc.,) that appear in the extracellular space are essential for
development. Cell surface receptors are mediators that trigger,
in cells having the same genome but becoming to differentiate
(i.e., to be different), varied gene transcription programs that
ultimately depend on the concentration of the endogenous
agonist. This non-genetic, i.e., epigenetic, mechanism may rely
on differential DNA methylation patterns but differential gene
regulation is probably a more likely mechanism. It is true
that the interest to link cell surface receptor activation to
epigenetic traits has been quite low. On the one hand, to
expand epigenetic options may lead to a more complex scenario,
but we feel the contrary, i.e., that it will serve to clarification
and consensus. On the other hand, either nutrient-based and
hormone-mediated gene regulation are considered epigenetic
mechanisms, or solid reasons are needed to exclude these
classical mechanisms while accepting those of atypical RNAs or
exosomes.
BIOCHEMISTRY-BASED PROPOSAL FOR
MORE EPIGENETIC FACTORS
The lack of consensus on a clear-cut operative definition on
Epigenetics impacts on the whole field. In their excellent
essay Deans and Maggert (2015) emphasize that the term has
“multiple meanings, describing vastly different phenomena.” We
consider that Epigenetics may be as wide-ranged as possible
to, subsequently, look for new names to describe some specific
factors/mediators/mechanisms. Our proposal to expand the
epigenetic window necessarily leads to more epigenetic players
(in mammals). Taking disease risk as an example, prediction
do require to know: (a) the DNA sequence, (b) factors directly
affecting DNA/chromosomal structure and (c) factors indirectly
affecting the expression of phenotype(s). Until now only factors
in (b) are considered epigenetic; we think that factors in (c)
are also epigenetic. Epigenetic is, in our opinion, the adjective
for genetic-independent variables that shape our phenotype
and even disease risk, disease progression and therapeutic
management.
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From a biochemist perspective, the Chemical aspects of
any Biological issue should be taken into account. First of
all, chemical reactions, from those in test tube to those
underlying epigenetic mechanisms in living animals, are ruled
by Thermodynamic laws and depend on “state” variables. As
usual, temperature and pressure are the first to consider. The
gene expression pattern and the resulting phenotype for a given
genome depend on whether the living being lives at sea level or in
a highmountain, and at below 0◦ in Siberia or at 35◦ in the tropic.
Water, which was highlighted by Aristotle as crucial for life, is
another factor but mainly in terms of humidity, for example, life
in a desert or in humid Amazonia.
A non-exhaustive enough list of epigenetic factors, mediators
and traits is provided in Table 1. The list focusses in mammals
and in factors that depend on the own characteristics of these
animals. Briefly, anything impacting on the five senses (sight,
smell, touch, taste, and hearing) is, to a greater or lesser degree,
affecting gene expression and, consequently, the phenotype. Take
for instance light exposure; surely, gene expression for a same
individual is different if living in Sweden -with few daily hours in
winter and many daily hours in summer- or in any country in the
Earth equatorial region. Food and life styles, education and social
interactions, are further factors that may help in identifying novel
epigenetic players, mechanisms and traits. In addition, epigenetic
features already accepted should be positioned within the bigger
picture.
INHERITANCE AND
TRANSGENERATIONAL TRANSMISSION
ISSUES
Inheritance is at the center stage in Epigenetics. Waddington
was interested in developmental mechanisms but did not care
much on inheritability, i.e., it was not fundamental for his
idea of Epigenetics. Holliday redefined Waddington’s concepts
and convinced many scientists that inheritance was a necessary
aspect in Epigenetics (Holliday, 1984, 1990, 1993, 2005, 2006).
In fact, the need of inheritable epigenetic characters is one
of the problems in reaching consensus. On the one hand,
epigenetic traits are first discovered and subsequently forced to
be inheritable. On the other hand, it is doubtful that the novel
epigenetic traits are inherited. The issue of inheritance is difficult
to reconcile and, from a biochemist point of view, it should
be secondary if not forgotten. Many of the differential traits
found even in identical monozygotic twins must be considered
as epigenetic and not necessarily acquired by inheritance
mechanisms during development.
Despite DNA methylation patterns may be clonally inherited
there is a reprograming of such patterns in the egg/embryo; they
are erased except in few imprinted gene sequences (Seisenberger
et al., 2012; Wasson et al., 2013; Monk, 2015; Zhou and Dean,
2015). Accordingly, histone modifications or DNA methylation
are very unlikely transgenerational epigeneticmechanisms. In the
absence of a breakthrough finding it will take time to confirm
epigenetic transgenerational transmission and the underlying
mechanisms. One of few examples in mammals derives from the
study of phenotypic traits in humans conceived in the 1944–
1945 Dutch famine (Veenendaal et al., 2013), in which health,
weight, body mass index rate, etc., of individuals conceived from
poorly feed parents or from well-feed parents were compared.
One interesting finding was a higher adiposity in the offspring of
prenatally undernourished fathers but not mothers (Veenendaal
et al., 2013). The topic has provided reviews where potential
mechanisms and myths on this topic are presented and discussed
(Dias and Ressler, 2014; Heard and Martienssen, 2014). We raise
the subject here because the candidates for transgenerational
transmission are the novel epigenetic mediators: miRNAs and
exosomes. They may travel from a given somatic cell to the
ovum or the spermatozoon to achieve the transgenerational
transmission. In this sense, these epigenetic mediators may
be inherited once integrated in spermatozoon precursors but,
very importantly, its epigenetic action is endocrine as they
should reach the spermatozoon precursors from elsewhere in the
human body. In the eventual case of maternal transmission, the
inheritability of epigenetic traits is very unlikely as ovules do not
divide but are present since early steps in mammalian life span,
i.e., the epigenetic factors must reach ovules one by one from
elsewhere in the female body.
EPIGENETIC-BASED THERAPY:
TARGETING NON-INHERITED EPIGENETIC
TRAITS?
Leaders in epigenetic research are expanding the sentence:
“we are what we eat” to something like “we are what
parents, grandparents, etc., ate.” In fact, Sales et al. (2017)
compile evidence to sustain that epigenetic transgenerational
transmission may be the basis for “non-genetic molecular legacy
of prior environmental exposures and influence transcriptional
regulation, developmental trajectories, and adult disease risk in
offspring.” The possibility of transmissible epigenetic factors
that may impact on the disease risk of offspring, even across
generations, is presented in several reviews (e.g., Nadeau, 2009;
Somer and Thummel, 2014; Hur et al., 2017; Weber-Stadlbauer,
2017). However, in daily practice clinicians assume that the
inherited risk of disease is due to DNAs inherited from father
and/or mother. This assumption seems appropriate for a variety
of diseases, for instance a higher risk of breast cancer in daughters
from mothers having had the disease would be likely due to
genetic factors. In other cases, where the genetic link is not
so evident, the epigenetic one should be considered. Expecting
to increase our knowledge on mechanisms linking epigenetic
transmission and disease risk, the research has devoted to
target epigenetic mechanisms to cure/combat diseases in gaining
momentum. Accordingly, one of the most sought potential of
Epigenetics is to translate preclinical research into “epigenetic”
medicines.
The most studied paradigmatic case in epigenetic-based
therapy is cancer. Evidence of epigenetic trait alterations in
cancers was expectable and, in fact, provided in many studies.
There are high expectations on targeting epigenetic DNA
methylation or histone acetylation to combat cancer and in
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TABLE 1 | Non-exhaustive list of Epigenetic factors, mediators and traits in mammals.
Factors Observations Example Inheritabilityb Endocrine-
like
Underlying
mechanism
Temperature Thermodynamic (state)
variablea
Living in Gobi desert vs. living in
Alaska
No No -
Pressure Thermodynamic (state)
variablea
Living at sea level vs. living in high
mountains
No No -
Gravity Physical factora Living on Earth surface vs. living in
Space station
No No -
Water Humidity Living in a desert vs. living in
Amazonia
No No -
Light Circadian rhythms Living in Sweden vs. living in Equator No Yes (partially) Partly known
Mediators Hormones/neuro-
transmitters
Regulating gene expression Steroids No Yes Partly known
Nutrients Regulating gene expression Lactose operonc No Yes Partly known
Covalent DNA
modification
Affecting DNA structure DNA methylases No No Unknown
Post-translational
modification of histones
Affecting
chromatin/chromosome
structure
Histone deacetylases No No Unknown
Transcription factors Regulating gene expression - No No Partly known
Atypical RNAs Regulating gene expression miR-29 micro RNAs, long non-coding
(ncRNAs)?
? Yes Unknown
Prion proteins Affecting cell fate Scrapie prion protein Yes ? Partly known
Traits Histone modifications - Histone acetylation ? - -
DNA modifications - DNA methylation Yes - -
Other To be discovered To be discovered - - -
Those that are currently more fashionable are highlighted in blue.
a In the absence of other impacting factors, state variables (also gravity) affect biological processes in a way that does not depend on the steps but on the initial and final conditions.
bClonal (not transgenerational) inheritability, i.e., from one parental to the two after-mitosis daughter cells. Inter- and transgenerational transmission are not considered in this article.
cAlthough not operating in mammals it was the first described mechanism of gene regulation in response to nutrient availability.
a recent review Perri et al. (2017) describe how anti-cancer
therapeutic approaches may take advantage of epigenetic control
of cell expression. In practice and as superbly reviewed by
Flavahan et al. (2017) fulfillment of expectations would require
“. . . test, validate (or refute) conceptual and mechanistic models
for cancer epigenetics, and place them in context with prevailing
genetic models.” At present, epigenetic traits may help in
better classification of cancer but the therapeutic prospects
are poor.
The inheritability of epigenetic mechanisms should be put
under a proper perspective; it appears as irrelevant in fighting
cancer since anti-cancer therapy attempts to kill malignant
cells before providing more daughter cancer cells. Epigenetic
mechanisms cannot be inherited in cells that do not divide;
neurons are the paradigm of such cells. Surely, there is now
accepted that a certain degree of neural development exists in
some restricted areas of the adult brain but, such possibility is
very limited in the aged brain and very compromised in diseases
of the central nervous system.
In our opinion, a fixation on cancer is limiting the
advance in epigenetic-based therapies for other diseases, e.g.,
neurodegenerative, in which cells should survive instead of
being killed. Epigenetic changes impacting on degenerating
neurons do not have much chance to be transmitted to
daughter cells. Current attempts to combat neurodegenerative
diseases, mainly Alzheimer’s, address a epigenetic mechanism
(histone acetylation, see Cuadrado-Tejedor et al., 2013 for
review) that is common to affected neurons and that is
not necessarily transmitted from cell to cell. It is true that
transcellular transmission of a pathogen triggering similar
epigenetic responses in connected neurons cannot be ruled
out. But even if this is the case, therapies based in epigenetic
traits should not essentially assume that the targeted trait is
inheritable/inherited or not. Other players may be identified in
the future, that also will tell which ones are really operating in
a physiologically relevant way and whether they may constitute
targets to combat diseases.
AUTHOR CONTRIBUTIONS
GN and EM-P have searched for the literature and contributed
to the writing. NF has contributed to the order of sections,
subsections and Table construction, i.e., to the overall design. RF
conceived the idea of the Perspective, contributed to the writing
and did the coordination.
ACKNOWLEDGMENTS
We are deeply indebted to Prof. Jaume Baguñà, from the
Genetics Department of the Faculty of Biology of the University
of Barcelona for enlightening discussions on Epigenetics, a
multifaceted fashionable topic.
Frontiers in Genetics | www.frontiersin.org 5 November 2017 | Volume 8 | Article 179
Navarro et al. Epigenetic Factors, Traits, and Mechanisms
REFERENCES
Celluzzi, A., and Masotti, A. (2016). How our other genome controls our epi-
genome. Trends Microbiol. 24, 777–787. doi: 10.1016/j.tim.2016.05.005
Cuadrado-Tejedor, M., Oyarzabal, J., Lucas, M. P., Franco, R., and García-Osta, A.
(2013). Epigenetic drugs in Alzheimer’s disease. Biomol. Concepts 4, 433–445.
doi: 10.1515/bmc-2013-0012
Deans, C., and Maggert, K. A. (2015). What do you mean, “epigenetic”? Genetics
199, 887–896. doi: 10.1534/genetics.114.173492
Deichmann, U. (2016). Epigenetics: the origins and evolution of a fashionable
topic. Dev. Biol. 416, 249–254. doi: 10.1016/j.ydbio.2016.06.005
Dias, B. G., and Ressler, K. J. (2014). Experimental evidence needed to demonstrate
inter- and trans-generational effects of ancestral experiences in mammals.
Bioessays 36, 919–923. doi: 10.1002/bies.201400105
Felsenfeld, G. (2014). A brief history of epigenetics. Cold Spring Harb. Perspect.
Biol. 6:a018200. doi: 10.1101/cshperspect.a018200
Flavahan, W. A., Gaskell, E., and Bernstein, B. E. (2017). Epigenetic plasticity and
the hallmarks of cancer. Science 357:eaal2380. doi: 10.1126/science.aal2380
Haig, D. (2004). The (dual) origin of epigenetics. Cold Spring Harb. Symp. Quant.
Biol. 69, 67–70. doi: 10.1101/sqb.2004.69.67
Heard, E., andMartienssen, R. A. (2014). Transgenerational epigenetic inheritance:
myths and mechanisms. Cell 157, 95–109. doi: 10.1016/j.cell.2014.02.045
Herring, S. W. (1993). Formation of the vertebrate face: epigenetic and functional
influences. Am. Zool. 33:472. doi: 10.1093/icb/33.4.472
Holliday, R. (1984). The biological significance of meiosis. Symp. Soc. Exp. Biol. 38,
381–394.
Holliday, R. (1990). DNAmethylation and epigenetic inheritance. Philos. Trans. R.
Soc. Lond. B. Biol. Sci. 326, 329–338. doi: 10.1098/rstb.1990.0015
Holliday, R. (1993). Epigenetic inheritance based on DNA methylation. EXS 64,
452–468. doi: 10.1007/978-3-0348-9118-9_20
Holliday, R. (2005). DNA methylation and epigenotypes. Biochemistry 70,
500–504. doi: 10.1007/s10541-005-0144-x
Holliday, R. (2006). Dual inheritance. Curr. Top. Microbiol. Immunol. 301,
243–256. doi: 10.1007/3-540-31390-7_9
Hur, S. S. J., Cropley, J. E., and Suter, C. M. (2017). Paternal epigenetic
programming: evolving metabolic disease risk. J. Mol. Endocrinol. 58,
R159–R168. doi: 10.1530/JME-16-0236
Jablonka, E., and Lamb, M. J. (2002). The changing concept of epigenetics. Ann. N.
Y. Acad. Sci. 981, 82–96. doi: 10.1111/j.1749-6632.2002.tb04913.x
Jacob, F., and Monod, J. (1961). Genetic regulatory mechanisms in the synthesis of
proteins. J. Mol. Biol. 3, 318–356. doi: 10.1016/S0022-2836(61)80072-7
Lange, S., Gallagher, M., Kholia, S., Kosgodage, U., Hristova, M., Hardy, J., et al.
(2017). Peptidylarginine deiminases—roles in cancer and neurodegeneration
and possible avenues for therapeutic intervention via modulation of
exosome and microvesicle (EMV) release? Int. J. Mol. Sci. 18:1196.
doi: 10.3390/ijms18061196
Monk, D. (2015). Germline-derived DNA methylation and early embryo
epigenetic reprogramming: the selected survival of imprints. Int. J. Biochem.
Cell Biol. 67, 128–138. doi: 10.1016/j.biocel.2015.04.014
Nadeau, J. H. (2009). Transgenerational genetic effects on phenotypic variation
and disease risk. Hum. Mol. Genet. 18, R202–R210. doi: 10.1093/hmg/ddp366
Perri, F., Longo, F., Giuliano, M., Sabbatino, F., Favia, G., Ionna, F., et al.
(2017). Epigenetic control of gene expression: potential implications
for cancer treatment. Crit. Rev. Oncol. Hematol. 111, 166–172.
doi: 10.1016/j.critrevonc.2017.01.020
Radulescu, R. T. (1995). From insulin, retinoblastoma protein and the insulin
receptor to a new model on growth factor specificity: the nucleocrine pathway.
J. Endocrinol. 146, 365–368. doi: 10.1677/joe.0.1460365
Radulescu, R. T. (2015). The nucleocrine pathway comes of age. Rom. J. Morphol.
Embryol. 56, 343–348.
Riggs, A., R. A., Martienssen, R., and Russo, V. (1996). Introduction. In Epigenetic
Mechanisms of Gene Regulation. Cold Spring Harbour, NY: Cold Spring
Harbour Laboratory Press.
Sales, V. M., Ferguson-Smith, A. C., and Patti, M.-E. (2017). Epigenetic
mechanisms of transmission of metabolic disease across generations. Cell
Metab. 25, 559–571. doi: 10.1016/j.cmet.2017.02.016
Seisenberger, S., Peat, J. R., Hore, T. A., Santos, F., Dean, W., and Reik, W. (2012).
Reprogramming DNA methylation in the mammalian life cycle: building and
breaking epigenetic barriers. Philos. Trans. R. Soc. B Biol. Sci. 368:20110330.
doi: 10.1098/rstb.2011.0330
Somer, R. A., and Thummel, C. S. (2014). Epigenetic inheritance of metabolic state.
Curr. Opin. Genet. Dev. 27, 43–47. doi: 10.1016/j.gde.2014.03.008
Veenendaal, M., Painter, R., de Rooij, S., Bossuyt, P., van der Post, J., Gluckman,
P., et al. (2013). Transgenerational effects of prenatal exposure to the 1944-45
Dutch famine. BJOG 120, 548–554. doi: 10.1111/1471-0528.12136
Waddington, C. (1939). An Introduction to Modern Genetics. New York, NY:
Macmillan Publishers Limited.
Waddington, C. (1942). The epigenome. Endeavour 1, 18–20.
Waddington, C. (1956). Embryology, epigenetics and biogenetics. Nature
177:1241. doi: 10.1038/1771241a0
Wasson, J. A., Ruppersburg, C. C., and Katz, D. J. (2013). Restoring totipotency
through epigenetic reprogramming. Brief. Funct. Genomics 12, 118–128.
doi: 10.1093/bfgp/els042
Weber-Stadlbauer, U. (2017). Epigenetic and transgenerational mechanisms in
infection-mediated neurodevelopmental disorders. Transl. Psychiatry 7:e1113.
doi: 10.1038/tp.2017.78
Wiklund, E. D., Kjems, J., and Clark, S. J. (2010). Epigenetic architecture and
miRNA: reciprocal regulators. Epigenomics 2, 823–840. doi: 10.2217/epi.10.51
Zhou, L., andDean, J. (2015). Reprogramming the genome to totipotency inmouse
embryos. Trends Cell Biol. 25, 82–91. doi: 10.1016/j.tcb.2014.09.006
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Navarro, Franco, Martínez-Pinilla and Franco. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Genetics | www.frontiersin.org 6 November 2017 | Volume 8 | Article 179
